Skip to main content

Table 3 ICU management and outcome data

From: Severe varicella-zoster virus pneumonia: a multicenter cohort study

Variables

 

VZV-related treatment

 Aciclovir

102 (100%)

 Aciclovir dose, mg/8 h

10 (10–10)

 Steroids

10 (10%)

 Immunoglobulins

1 (1%)

 Systemic antibiotics at ICU admission

62 (61%)

Primary source of bacterial co-infection (n = 40, 39%)

 Lung

24 (60%)

 Bloodstream

8 (20%)

 Skin

4 (10%)

 Other

4 (10%)

Life-sustaining therapies

 Non-invasive mechanical ventilation

29 (28%)

 Invasive mechanical ventilation

52 (51%)

 Vasopressors

36 (35%)

 Renal replacement therapy

24 (24%)

ARDS criteria according to the Berlin definition (n = 42, 41%)

 Mild ARDS

8 (19%)

 Moderate ARDS

10 (24%)

 Severe ARDS

24 (57%)

Other interventions

 Neuromuscular blockers

26/52 (50%)

 Prone positioning

14/52 (28%)

 Veno-venous ECMO

7/52 (13%)

Outcome data

 ICU length of stay (days)

8 (4–16.75)

 Hospital length of stay (days)

14 (9–33)

 ICU mortality

17 (17%)

 Hospital mortality

24 (24%)

  1. Values are shown as n (%) or median (25th–75th percentiles)
  2. AKI acute kidney injury, ARDS acute respiratory distress syndrome, ECMO extra-corporeal lung oxygenation, ICU intensive care unit, VZV varicella-zoster virus